Hypersensitivity: Clinical Trials

6298 completed, 1075 unknown, 737 recruiting, 518 terminated. 2336 Not applicable, 1773 Phase 2, 1464 Phase 3, 945 Phase 1, 891 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	2336	Completed 1416, Unknown 366, Recruiting 198, Not yet recruiting 110, Terminated 97, Withdrawn 72, Active not recruiting 49, Enrolling by invitation 20, Suspended 8
Phase 2	1773	Completed 1220, Terminated 160, Recruiting 112, Unknown 91, Withdrawn 81, Active not recruiting 56, Not yet recruiting 45, Enrolling by invitation 8
Phase 3	1464	Completed 1106, Unknown 80, Recruiting 75, Terminated 67, Withdrawn 52, Active not recruiting 47, Not yet recruiting 27, Enrolling by invitation 8, Suspended 2
Phase 1	945	Completed 700, Terminated 79, Recruiting 54, Unknown 42, Withdrawn 33, Active not recruiting 17, Not yet recruiting 17, Enrolling by invitation 2, Suspended 1
Phase 4	891	Completed 621, Unknown 94, Terminated 63, Recruiting 39, Withdrawn 26, Active not recruiting 23, Not yet recruiting 23, Enrolling by invitation 2
Early Phase 1	70	Completed 43, Unknown 8, Terminated 7, Enrolling by invitation 4, Active not recruiting 3, Recruiting 3, Not yet recruiting 1, Withdrawn 1

Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis		Withdrawn	Massachusetts General Hospital		2030-01-01	2026-01-16
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS AYURVEDA treatment protocol, Control(Citrizine 10mg) - Allergic Rhinitis (AR)	Not applicable	Not yet recruiting	Amrita Vishwa Vidyapeetham	104	2028-06-30	2026-06-04
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis	Phase 2	Not yet recruiting	Enzychem Lifesciences Corporation	150	2027-05-01	2026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Pfizer	90	2027-05-01	2026-09-16
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function	Phase 2	Not yet recruiting	Foresee Pharmaceuticals Co., Ltd.	135	2027-03-01	2026-07-20
UNC Cashew Sublingual Immunotherapy Cashew sublingual immunotherapy, Placebo sublingual immunotherapy - Cashew Nut Allergy, Tree Nut Allergies	Phase 2	Not yet recruiting	University of North Carolina, Chapel Hill	45	2027-03-01	2026-10-20
Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy	Phase 2	Withdrawn	Boston Children's Hospital		2027-02-01	2024-11-26
Prevent Wheeze Trial Dexamethasone 0.6 mg/kilogram body weight single dose, Placebo - Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing	Phase 4	Not yet recruiting	Norwegian University of Science and Technology	486	2027-02-01	2026-10-05
Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome	Phase 2	Not yet recruiting	University Hospital, Lille	96	2027-01-06	2026-05-15
Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies Initial assesment interwiew, Intake Interview with the Patient - Severe Asthma		Not yet recruiting	University Hospital, Angers	20	2027-01-04	2026-10-02
GOAt Milk Formula-based Ladder Versus Cow's Milk Ladder oral food challenge (OFC) - Food Allergy, Cow's Milk Protein Allergy	Not applicable	Not yet recruiting	Medical University of Warsaw	92	2027-01-02	2026-08-31
Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy Partially Hydrolyzed Whey Protein Formula, Intact Cow's Milk Protein Formula - Mild Allergic Symptoms in Infants, Infant Feeding Intolerance	Not applicable	Not yet recruiting	Ruijin Hospital	160	2027-01-01	2026-08-18
Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma	Phase 2	Not yet recruiting	Indiana University	30	2027-01-01	2026-02-27
Nebulized Ketamine for Severe Asthma Attacks in Children Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma	Phase 2	Not yet recruiting	Sultan Qaboos University	60	2027-01-01	2026-07-27
Educational Eczema Video Intervention in-clinic video intervention, at home video intervention - Eczema	Not applicable	Withdrawn	Boston Children's Hospital		2027-01-01	2026-10-19
Sustained Asthma Remission and Reduced Relapse Using a Comprehensive Management Strategy (SARRE-COMS) Comprehensive Biomarker-Guided Management Strategy, Standard of Care - Asthma (Diagnosis)	Not applicable	Not yet recruiting	Hana Serajeddini	50	2026-12-02	2026-09-25
Allergy, Asthma, and Atopic Eczema in Finland No intervention, No Intervention: Observational Cohort - Asthma, Asthma in Children		Not yet recruiting	Tampere University	1200000	2026-12-01	2026-10-15
Development and Validation of the Indian Asthma Care Bundle for Reducing Readmission and Improving Post-hospitalisation Care After Discharge From Hospital Due to an Acute Asthma Exacerbation Indian Asthma Care Bundle (I-ACB) - Asthma Exacerbation, Asthma (Diagnosis)	Not applicable	Not yet recruiting	Ahmedabad University	260	2026-12-01	2026-09-11

Showing 20 of 9575. Sign in to see all of them.

Narrower conditions

Asthma (4460)  ·  Dermatitis, Atopic (1509)  ·  Rhinitis, Allergic (680)  ·  Pulmonary Disease, Chronic Obstructive (451)  ·  Rhinitis, Allergic, Seasonal (384)  ·  Eczema (367)  ·  Food Hypersensitivity (355)  ·  Sarcoidosis (248)  ·  Eosinophilic Esophagitis (234)  ·  Conjunctivitis, Allergic (197)  ·  Chronic Urticaria (191)  ·  Rhinitis, Allergic, Perennial (178)  ·  Angioedemas, Hereditary (169)  ·  Peanut Hypersensitivity (165)

Broader conditions

Immune System Diseases (9511)  ·  Hypersensitivity, Immediate (8459)  ·  Respiratory Tract Diseases (5767)  ·  Respiratory Hypersensitivity (5552)  ·  Lung Diseases (4564)  ·  Bronchial Diseases (4528)  ·  Lung Diseases, Obstructive (4452)  ·  Skin and Connective Tissue Diseases (2282)  ·  Skin Diseases (2189)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1859)  ·  Genetic Diseases, Inborn (1808)  ·  Pathological Conditions, Signs and Symptoms (1638)  ·  Skin Diseases, Eczematous (1588)  ·  Dermatitis (1559)

Interventions

Fluticasone (244)  ·  Budesonide (202)  ·  montelukast (179)  ·  Albuterol (162)  ·  Omalizumab (159)  ·  dupilumab (156)  ·  Mometasone Furoate (107)  ·  Formoterol Fumarate (105)  ·  Beclomethasone (88)  ·  Fluticasone-Salmeterol Drug Combination (87)  ·  Salmeterol Xinafoate (81)  ·  Blood Specimen Collection (80)  ·  Budesonide, Formoterol Fumarate Drug Combination (80)  ·  Sodium Chloride (66)  ·  benralizumab (57)

Sponsors

GlaxoSmithKline (346)  ·  AstraZeneca (344)  ·  Novartis Pharmaceuticals (156)  ·  Organon and Co (152)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (115)  ·  Sanofi (97)  ·  Pfizer (89)  ·  National Heart, Lung, and Blood Institute (NHLBI) (82)  ·  Assistance Publique - Hôpitaux de Paris (77)  ·  Boehringer Ingelheim (71)  ·  Chiesi Farmaceutici S.p.A. (62)  ·  Johns Hopkins University (60)  ·  Imperial College London (58)  ·  Regeneron Pharmaceuticals (58)  ·  University of North Carolina, Chapel Hill (56)

Countries

United States (3398)  ·  Germany (937)  ·  Canada (916)  ·  United Kingdom (889)  ·  France (719)  ·  China (600)  ·  Poland (540)  ·  Spain (527)  ·  Italy (465)  ·  Netherlands (360)  ·  Japan (337)  ·  Australia (334)  ·  South Korea (287)  ·  Belgium (273)  ·  Hungary (269)

Results publications

PMID 36472162, PMID 36326435, PMID 27881132, PMID 35636689, PMID 39393433, PMID 39588375, PMID 31319851, PMID 33006765, PMID 33305842, PMID 33826132, PMID 34389504, PMID 29400693, PMID 32926419, PMID 35691614, PMID 42162528, PMID 33217063, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38127464, PMID 38814736, PMID 38896380, PMID 40993471, PMID 19001265, PMID 26704701, PMID 30954640, PMID 33165005, PMID 34037993, PMID 36408587, PMID 36853224, PMID 39104653, PMID 40028832, PMID 18331513, PMID 20818886, PMID 22329608, PMID 23312695, PMID 23878046, PMID 24184147, PMID 24712435, PMID 28065396, PMID 29174062, PMID 29536781, PMID 29656145, PMID 31066001, PMID 32180164, PMID 33453450, PMID 34098955, PMID 34142350, PMID 35061234, PMID 35342978

NIH funding

2018 (64), 2023 (52), 2019 (43), 2015 (42), 2017 (42), 2014 (41), 2016 (41), 2025 (34), 2009 (33), 2008 (18), 2004 (9), U10HL098115 (8), U10HL074212 (6), 2005 (5), P01HL107202 (5)